This week's events have highlighted the dangers and rapidity with which bacterial meningitis can manifest. A person can appear perfectly healthy one moment, and within 24 hours, could be facing an infection that reaches the brain's linings and sepsis.
The UK Health Security Agency (UKHSA) was notified of the first case on March 13, and public warnings were issued two days later, on Sunday night. So far, the number of infections linked to this outbreak has reached 29, with two fatalities reported, and the outbreak has been characterized as 'unprecedented.'
The incident began with a gathering considered a catalyst for spreading at Club Chemistry in Canterbury from March 5 to 7. The incubation period, which is the time from exposure to the onset of symptoms, can be up to ten days, meaning cases related to those evenings may still emerge in the coming days. Nevertheless, only two new cases were reported on Friday, which is encouraging but does not necessarily indicate that the peak of the outbreak has passed.
As part of the response, approximately 10,000 people have received antibiotics aimed at eliminating the meningococcal bacteria and preventing the disease from developing or spreading. A wide contact tracing campaign has identified around 10,000 individuals as potential contacts.
Currently, confirmed and suspected cases are directly associated with Kent, but some students left the university to return home upon hearing the news, which raises the possibility of asymptomatic carriers transmitting the bacteria to other regions. Despite the link to this outbreak, it's essential to remember that the rate of systemic bacterial meningitis cases not associated with an outbreak is roughly one case daily under normal circumstances.
Health Minister Wes Streeting has asked government vaccine advisers to review the evidence. There is no dispute regarding the effectiveness of the MenB vaccine — it works — but the debate focuses on its cost-effectiveness and the allocation of resources by the National Health Service. It's noted that the private purchase cost of the vaccine is about £220. Over a decade ago, the Joint Committee on Vaccination and Immunisation concluded that the MenB vaccine was cost-effective for the most vulnerable infants and young children but was not deemed cost-effective for adolescents and young adults.
A preliminary genetic analysis of the bacteria causing the outbreak was completed on Thursday, showing similarities to strains circulating in the UK since 2021, indicating that the vaccine should protect against them. However, more detailed analyses are needed, as small mutations can significantly alter the bacteria's behavior. Experts are currently working to determine whether there are changes that make the strain more transmissible or more capable of invading the body or accessing brain tissues.
Several aspects of this outbreak remain puzzling. Is the entire explanation rooted in the bacteria's properties, or have other factors contributed to its expansion and rapidity? Discussions have surfaced about the involvement of vaping in a crowded club, which is an unhealthy behavior but not extraordinary, and there is no definitive evidence linking it to the outbreak. It has also been suggested that lockdowns during the COVID-19 pandemic may have reduced adolescents' exposure to meningococcal bacteria, leading to weakened immunity in this age group. Additionally, a dust cloud from the Sahara was noted passing over Europe and the UK around the time the outbreak began; this dust is known to irritate respiratory passages, possibly facilitating the bacteria's transition from its harmless presence in the throat or nose to invading the body, akin to the reason behind the Meningitis Belt in Africa.
Are any of these factors a direct cause? Or is the outbreak a result of the accumulation of small, combined factors? These questions remain central to the investigations of experts and health authorities as efforts continue in reporting, tracing, genetic analysis, and reviewing preventative policies.